ALLERGAN USA, INC. for ALLERGAN USA, INC.

Trade (domestic/foreign) TRD

Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation. Promoting the social contract with patients to ensure they have affordable access to critical innovative medicines.

Contacted: Patent & Trademark Office (PTO); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Copyright/Patent/Trademark CPT

Patent Reform Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS)

Pharmacy PHA

Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); Food & Drug Administration (FDA); SENATE

Taxation/Internal Revenue Code TAX

Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.

Foreign entity interest: Allergan plc, as the indirect parent of Allergan USA, Inc., has an interest to the extent that policy affects the tax treatment of its subsidiaries, foreign and domestic.

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); SENATE

Medicare/Medicaid MMM

Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases. Protecting patients from demonstrations, regulations, and rules that would limit access to life-saving medicines.

Contacted: SENATE; Patent & Trademark Office (PTO); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.

Contacted: Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Health Issues HCR

Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 2680 (114th), H.R. 2646 (114th)